PolyPid names Dr. Nurit Tweezer-Zaks CMO

PolyPid Ltd., an Israel-based biopharmaceutical company, filed a Form 6-K to furnish a press release announcing the appointment of Dr. Nurit Tweezer-Zaks as its Chief Medical Officer.

Rhea-AI Filing Summary

PolyPid Ltd., an Israel-based biopharmaceutical company, filed a Form 6-K to furnish a press release announcing the appointment of Dr. Nurit Tweezer-Zaks as its Chief Medical Officer. This leadership change relates to oversight of the company’s medical and clinical activities.

The filing also states that the first and third paragraphs of the press release, along with its “Forward-Looking Statements” section, are incorporated by reference into several of PolyPid’s effective registration statements on Forms F-3 and S-8, so that these disclosures become part of those offering documents going forward.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PolyPid Ltd. (PYPD) report in this Form 6-K?

PolyPid Ltd. filed a Form 6-K to furnish a press release announcing the appointment of Dr. Nurit Tweezer-Zaks as the company’s new Chief Medical Officer and to incorporate parts of that release into its existing registration statements.

Who was appointed Chief Medical Officer at PolyPid Ltd. (PYPD)?

PolyPid Ltd. appointed Dr. Nurit Tweezer-Zaks as its Chief Medical Officer, as disclosed in the press release furnished with the Form 6-K.

How does this Form 6-K affect PolyPid Ltd.’s (PYPD) registration statements?

The filing incorporates the first and third paragraphs of the press release and its “Forward-Looking Statements” section into PolyPid’s registration statements on Form F-3 and Form S-8, making those disclosures part of the relevant offering documents from the submission date.

Which PolyPid (PYPD) registration statements are referenced in this Form 6-K?

The Form 6-K references PolyPid’s registration statements on Form F-3 (File Nos. 333-276826, 333-280658, 333-281863, 333-284376 and 333-289034) and Form S-8 (File Nos. 333-239517, 333-271060, 333-277703 and 333-280662).

Does the PolyPid Ltd. (PYPD) Form 6-K include financial results?

No, this Form 6-K focuses on the appointment of a new Chief Medical Officer and the incorporation of parts of a related press release into existing registration statements; it does not present financial results.

Who signed the PolyPid Ltd. (PYPD) Form 6-K?

The Form 6-K was signed on behalf of PolyPid Ltd. by Dikla Czaczkes Akselbrad, who is identified as the company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2025 - 08:05 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: August 2025

Commission File Number: 001-38428

PolyPid Ltd.

(Translation of registrant’s name into English)

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

Attached hereto and incorporated herein is PolyPid Ltd.’s (the “Registrant”) press release issued on August 12, 2025, titled “PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer.” 

The first and the third paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034)  and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703 and File No. 333-280662) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release issued by PolyPid Ltd. on August 12, 2025, titled “PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer.”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	POLYPID LTD.
Date: August 12, 2025	By:	/s/ Dikla Czaczkes Akselbrad
		Name	: Dikla Czaczkes Akselbrad
		Title:	Chief Executive Officer

3